Enzo Biochem

356 articles about Enzo Biochem

• Enzo Disappointed in Harbert’s Lawsuit Aimed at Disenfranchising Shareholders

  2/7/2020

  Feb. 7, 2020 13:00 UTC Activist Attempts to Prevent Enzo Shareholders from Exercising Their Right to Vote on Board Expansion Proposal NEW YORK--( BUSINESS WIRE )-- Enzo Biochem, Inc. (NYSE:ENZ) (the “Company”) today disclosed that Harbert Discovery Fund, LP (“Harbert”) filed a lawsuit against the Company and the members of its board of directors (“Board”) in the U.S. District Court for the Southern District of New York. Enzo commented as follows: “We are disappoin

• Enzo Comments on Harbert’s Reaction to Providing Enzo Shareholders Additional Choices

  1/30/2020

  Enzo Biochem, Inc. (NYSE:ENZ) today commented on Harbert’s press release in reaction to Enzo’s announcement that it is providing its shareholders with additional choices:

• Enzo Biochem Proposes to Increase Size of Board and Will Appoint Additional Highly Qualified, Diverse Independent Director in Near Future

  1/28/2020

  Withdraws Nomination of Dr. Bruce Hanna, Ph.D.; Current Nominees Rebecca Fischer and Barry Weiner Remain.

• Harbert Discovery Fund Sends Letter to Fellow Enzo Biochem Shareholders

  1/27/2020

  Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively “HDF”), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), today sent a letter to shareholders in connection with its efforts to elect two highly-qualified, fresh voices – Fabian Blank and Peter Clemens – to the Company’s Board of Directors (the “Board”) at its 2019 Annual Meeting of Shareholders

• Enzo Biochem Responds to Series of Misleading and Inaccurate Statements from Activist Hedge Fund Harbert

  1/13/2020

  The Board of Directors of Enzo Biochem, Inc. responded to a series of misleading and inaccurate statements in an investor presentation and press release filed by activist investor Harbert Discovery Fund regarding the Company’s significant accomplishments.

• 

  BioSpace Movers & Shakers, Jan. 3

  1/3/2020

  Pharma, biotech and life sciences companies boost their leadership ranks with this weeks Movers & Shakers.

• Enzo Biochem Appoints Rebecca J. Fischer to Board of Directors

  12/31/2019

  Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today announced it has appointed industry healthcare veteran and leader Rebecca J. Fischer to its Board of Directors.

• Enzo Biochem Reports Fiscal First Quarter Results

  12/10/2019

  Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today reported results for the fiscal first quarter ended October 31, 2019.

• Enzo Biochem Issues Open Letter to Shareholders - Dec. 5, 2019

  12/5/2019

  Short-Term Activist Harbert, With No Sector Experience and No Plan for Enzo, Seeks Fire Sale of Company at Depressed Prices

• Enzo Biochem Schedules Teleconference to Discuss First Quarter 2020 Results Tuesday, December 10, 2019 At 4:30 PM E.T.

  12/5/2019

  Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2020 first quarter results on Tuesday, December 10, 2019, at 4:30 PM E.T.

• Enzo Biochem Reports Fiscal Fourth Quarter and Full Year Financial Results

  10/15/2019

  Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics, clinical lab, and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today reported results for the fiscal fourth quarter and year ended July 31, 2019.

• Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter and Fiscal Year 2019 Results Tuesday, October 15, 2019 at 4:30 PM E.T.

  10/11/2019

  Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2019 fourth quarter and fiscal year 2019 results on Tuesday, October 15, 2019, at 4:30 PM E.T.

• New York State Health Department Approves Hepatitis B Virus Quantitative Clinical Assay

  9/24/2019

  Enzo Biochem, Inc. (NYSE: ENZ) today announced that its wholly owned subsidiary, Enzo Clinical Labs, Inc. has received New York State approval for its AmpiProbe® HBV viral load monitoring assay for Hepatitis B virus (HBV) based on the Enzo assay’s performance versus an FDA-approved comparator product.

• Harbert Discovery Fund Nominates Two Highly-Qualified Independent Candidates to Enzo Biochem Board

  9/17/2019

  Sends Letter to Shareholders Highlighting Enzo’s Sustained History of Underperformance and Missteps of Current Entrenched Board and Management Team

• Enzo Biochem, Inc. Announces Issuance of United States Patent for Advanced Nucleic Acid Hybridization Probe Technology for Clinical and Research Applications

  8/5/2019

  Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and therapeutics company, today announced the issuance of U.S. Patent No. 10,323,272 entitled Nucleic Acid Probes for In Situ Hybridization.

• Enzo Biochem Announces Key Transformative Initiatives to Propel and Accelerate Growth In its Lab Business

  7/11/2019

  New York State Health Department Approval of Oral and Rectal STI Testing

• Enzo Biochem Reports Fiscal Third Quarter and Nine Months Operating Results

  6/10/2019

  Enzo Biochem, Inc. (NYSE:ENZ), an integrated life sciences company focused on commercializing innovative diagnostic and therapeutics products, today reported results for the fiscal quarter and nine months ended April 30, 2019.

• Enzo Biochem Schedules Teleconference to Discuss Third Quarter 2019 Results Tuesday, June 11, 2019 at 8:30 AM E.T.

  6/5/2019

  To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024. When prompted, use PIN number 1870919

• Enzo Biochem Inc. Announces Issuance of United States Patent for Treatment of Liver Cancer Using Ozanimod

  5/10/2019

  Enzo Biochem, Inc. (NYSE:ENZ) today announced that on May 7, 2019 it was issued U.S. Patent No. 10,278,960 entitled “Sphingosine Pathway Modulating Compounds for the Treatment of Cancers” that is directed to methods for treating hepatocellular carcinoma (HCC), the most common human liver cancer, using the compound Ozanimod.

• Enzo Biochem Reports Second Fiscal Quarter and First Half 2019 Results and Reports Progress on Its Investments and Strategic Goals

  3/11/2019

  Enzo Biochem, Inc. reported results for the fiscal quarter and first half ended January 31, 2019 along with providing more detail on its investments in the development of novel diagnostic system and centralized clinical services.